August 1, 2022, Shanghai, China

Hua Medicine (the “Company”, stock code: 2552.HK) today announces that Mr. Qing Dong has been appointed as Vice President of the Pharmaceutical Commercialization Division of Hua Medicine. Mr. Qing Dong will be fully responsible for the development of dorzagliatin commercialization  strategy and the strategic management of the pharmaceutical commercialization  team  to accelerate the adoption of dorzagliatin by Type 2 diabetes patients in China.

Teamed up with Bayer China, Hua Medicine is ready to advance  dorzagliatin into commercialization.
Link: 糖尿病患者如何保护胰岛β细胞功能？多格列艾汀争做胰岛β细胞的“护花使者”

Mr. Qing Dong graduated from the School of Pharmacy, Fudan University with a major in pharmacy.  He has nearly 30 years of extensive experience in helping pharmaceutical commercialization of large multi-national pharmaceutical companies in China. Before joining Hua Medicine, Mr. Qing Dong served as National Commercial Senior Director of Gilead Sciences Shanghai Pharmaceutical Technology Co., Ltd. and as a National Commercial Director in Consumer Health at Bayer Healthcare Company and at Sino-American Shanghai Squibb Pharmaceuticals Ltd.  He also served as National Market Access Manager at Sandoz (China) Pharmaceutical and National Pricing Manager at Eli Lilly Asia Inc. Mr. Qing Dong’s business insight and international vision will strongly benefit the commercial launch and promotion of dorzagliatin in Chinese market.

With the success development of dorzagliatin in China, Hua Medicine has established a new division in the United States under the leadership of CTO Dr Fuxing Tang and also invited two industry executives  Dr. Paul Chew and Dr. Ji Zhang to serve as  Senior Scientific Advisor of Hua Medicine to guide dorzagliatin global product development with a focus on the United States market.

Dr Paul Chew, M.D., previously served as Senior Vice President, Global Chief Medical Officer and Head of US R&D at Sanofi Pharma, responsible for Global Medical Affairs, Pharmacovigilance, Health Outcomes, Medical Information, and Regulatory teams of more than 2,000 global staff. Dr Chew participated in the development of multiple commercial products include Plavix®, Taxotere®, Lovenox®, Lantus®, and several other launched products. Dr. Chew has over 30 years of extensive experience in clinical development and internet health in global pharmaceutical companies. Currently, he serves as an advisor for various innovative institutions including Cormedix, Phesi and Aris Global as well as the George Washington University Milken School of Public Health to bring innovation to patients. Dr. Chew is also recognized as an expert with extensive experience in the prevention and management of diabetes and other chronic conditions.

Dr Ji Zhang, Ph.D. in Statistics, previously served as a Senior Vice President of Sanofi Research and Development Operations. He led a global team of more than 4,000 scientists in over 30 countries, and has more than 30 years of experience in innovative drug R&D operations and management in pharmaceutical industry. Dr. Ji Zhang has strategic vision and outstanding operational leadership in clinical development & operations, translational medicine, early development, investment portfolio & project management, digital strategy and implementation. He also has extensive experience in preclinical safety, synthetic and biologic CMC, and medical affairs. He has demonstrated exceptional leadership in transformational changes of enterprises, people development and team building, and global/multi-culture versatility. Dr. Ji Zhang has been extensively published in clinical development research areas with more than 100 peer reviewed scientific papers and technical reports, and has played an important leadership roles in the development and marketing of multiple innovative medicines, including Singulair®, Jevtana®, Multaq®, Toujeo®, Soliqua®, Aubagio®, Dupixent®, Praluent®, Kevzara®, Cerdelga®, Sarclisa®, among others. Dr. Ji Zhang has also achieved industry leading achievements in business model innovation, productivity enhancement and quality control.

Dr. Li Chen, Founder and CEO of Hua Medicine, said, “With success of the global first-in-class dorzagliatin, Hua Medicine is entering into a new era of commercialization and globalization. We believe that under the leadership of Mr. Qing Dong, Hua Medicine can build an excellent commercialization team and bring dorzagliatin to our patients at the fastest speed to release the burden of diabetes and return to healthy life. At the same time, we are also planning to expand our innovation to the rest of world with the help of Dr. Paul Chew and Dr. Ji Zhang.  We are determined to innovate new solutions for diabetes patients in China and around the world.”

About Dorzagliatin
Dorzagliatin is an oral investigational glucokinase allosteric activator (GKA) targeting on  impaired glucose sensor glucokinase (GK) in pancreas, intestine and liver. Dorzagliatin regulates glucose stimulated secretion of the glycemic controlling hormones insulin, GLP-1 and glucagon in diabetes patients which lead to the improvement of early phase insulin secretion and disposition index that are important to restore the glucose homeostasis and achieve diabetes remission. Results from two Phase III registered trials of dorzagliatin monotherapy for drug naive T2D patients and combination of dorzagliatin and metformin in the metformin tolerated T2D patients, together with data from combination studies of dorzagliatin with sitagliptin (DPP-4 inhibitor) and empagliflozin (SGLT-2 inhibitor), showed that dorzagliatin significantly improves glycemic control with effective reduction of post prandial glucose and very low risk of hypoglycemia. Dorzagliatin is well tolerated and safe in the patient population tested. Dorzagliatin demonstrated a linear correlation between drug dose and plasma exposure with high target organ distribution in the pancreas, intestine and liver. It showed low renal excretion in human and similar pharmacokinetic profiles at End Stage Renal Disease (ESRD) patients and healthy subjects, which suggest it can be readily used in diabetes kidney disease (DKD) patients without dose adjustment. The unique mechanism of action together with desirable pharmacokinetic and safety profile make dorzagliatin a new class of anti-diabetes therapy which has the potential to bring diabetes to remission either alone or in combination with existing medicines.

About Hua Medicine
Hua Medicine is an innovative drug development company found in China focused on developing novel therapies for patients worldwide with unmet medical needs. Based on global resources, Hua Medicine teams up with global high-caliber people to develop breakthrough technologies and products, which contribute a global innovation in diabetes care. Targeting on glucose sensor glucokinase, dorzagliatin, as its cornerstone product, restores glucose sensitivity in T2D patients and has completed SEED and DAWN registration trials, with its NDA accepted by the National Medical Products Administration (NMPA) in China. This first-in-class glucokinase activator has demonstrated its potential of achieving diabetes remission to help millions of diabetic patients around the world.

For more information
Hua Medicine
Website: www.czfubang.com
Investors
Email: ir@czfubang.com
Media
Email: pr@czfubang.com

Disclaimer
Hua Medicine has not made any express or implied, statutory or other guarantees for its products and/or services through this website, and shall not bear any legal liability. In particular, we do not make any representations or guarantees about whether any content displayed on this website will infringe the rights of the third party, nor do we assume any legal liability. The information published on this website is general information for your reference only, which may be risks and defects involved. In view of the massive amount of information on this website, we cannot review the legitimacy, authenticity, and accuracy of the information one by one, and you shall judge this with caution by yourself. This website may contain statements relating to medical conditions, medical treatments or methods and product information, such information will only be used as basic knowledge popularization. Under no circumstances will it replace professional medical guidance in any way, and should it be considered as part of medical advice or diagnosis. This website shall not be construed as containing any advertising or sales intent. You shall always seek the advice of your physician or other qualified healthcare professionals with any questions you may have regarding a medical condition. Hua Medicine makes no warranties or representations of any kind as to its accuracy, currency or completeness regarding the content and information contained herein. You agree that access to and use of this website and the content thereof is at your own risk.  The content posted on this website does not mean that we agree with the relevant content, opinions, views or positions.